Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action.[2][3] The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.[2] The company has sixteen products in its pipeline, in various stages of development.[2]

ProductIndicationDevelopment phaseNotes
ARO-HBV[2]Hepatitis BIn clinic, phase 2Licensed with Janssen, Phase 2
ARO-AAT[2]Alpha-1 antirypsin deficiencyIn clinic, phase 3Orphan Drug designation, partnered with Takeda
ARO-APOC3[2]HypertriglyceridemiaPhase 2, 3Orphan Drug designation, Fast Track Designation, Phase 3 for FCS, Phase 2 for expanded populations
ARO-HIF2[2]Renal cell carcinomaPreclinical Second generation being worked on presumably
ARO-ENaC[2]Cystic fibrosisPreclinical Second generation being worked on in preclinic
ARO-ANG3[2]DyslipidemiaIn clinic, Phase 2Orphan Drug designation
Olpasiran/ AMG 890[2]Cardiovascular diseaseIn clinic, phase 3Partnered with Amgen
ARO-PNPLA3 NASH In clinic, Phase 1 License returned to ARWR
ARO-HSD NASH In clinic, Phase 1 Licensed to GSK
ARO-C3 Complement Mediated Disease In clinic, Phase 1
ARO-MUC5AC Muco-obstructive In clinic, Phase 1
ARO-RAGE Inflammatory In clinic, Phase 1
ARO-MMP7 Idiopathic Pulmonary Fibrosis In clinic, Phase 1
ARO-COV Covid-19 Preclinical
ARO-DUX4 FSHD Preclinical
HZN-457 Gout In clinic, Phase 1 Partnered with Horizon
Arrowhead Pharmaceuticals, Inc.
TypePublic
IndustryBiotechnology
Founded1 January 2004 Edit this on Wikidata
HeadquartersPasadena, California, U.S.
Key people
Christopher Anzalone, Ph.D., president and chief executive officer

Javier San Martin, M.D., Chief Medical Officer Ken Myszkowski, MBA, CPA, chief financial officer

James Hamilton, M.D., MBA, Chief Discovery and Translational Medicine
RevenueIncrease $243.2 million(2022)[1]
Number of employees
376
Websitearrowheadpharma.com


In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio, and assets from Novartis.[4][5]

In April 2016, it was announced that the former company name, Arrowhead Research Corporation, will be changed to Arrowhead Pharmaceuticals, Inc.[6]

In September 2016, Arrowhead entered into two collaboration and licensing agreements with Amgen. Under the deals, Amgen received a worldwide exclusive license to Arrowhead’s ARO-LPA RNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.[7]

On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. As part of the deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three more RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.[8]

References
  1. https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-reports-fiscal-2022-year-end-results. {{cite web}}: Missing or empty |title= (help)
  2. "arwr-10q_20170331.htm". www.sec.gov. Retrieved 2017-05-17.
  3. "8-K". www.sec.gov. Retrieved 2017-05-17.
  4. "Arrowhead buys Novartis' RNAi portfolio". Reuters. 2017-03-05. Retrieved 2017-05-17.
  5. Staff (1 April 2015). "Novartis Sells RNAi R&D Portfolio to Arrowhead in $35M Agreement". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10.
  6. "Arrowhead Research Changes Name to Arrowhead Pharmaceuticals". www.businesswire.com. 2016-04-06. Retrieved 2020-04-06.
  7. "Amgen, Arrowhead team up on gene-therapies for heart disease". Reuters. 2017-09-29. Retrieved 2017-05-17.
  8. "Arrowhead Enters $3.7 Billion License and Collaboration". Marketwatch. 2018-10-04. Retrieved 2018-10-04.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.